Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2013

01-12-2013 | Research Article

The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis

Authors: Changxi Zhou, Huaijie An, Mingdong Hu, Qinghui Liu, Peiliang Geng, Jiancheng Xu, Baojun Sun, Changting Liu

Published in: Tumor Biology | Issue 6/2013

Login to get access

Abstract

Several studies have investigated the association between Cyclin D1 (CCND1) G870A genetic polymorphism and lung cancer susceptibility, but the results were inconclusive. The aim of this meta-analysis was to summarize available evidence for such a relationship. The reviewers made use of MEDLINE, EMBASE, and BIOSIS databases. The relevant data were independently extracted by two reviewers. The odds ratio (OR) with 95 % confidence interval (CI) was selected as the principal outcome measure. The heterogeneity test, the publication bias test, and the sensitivity analysis were performed. Overall, a total of 10 case–control studies were included. Our meta-analysis indicated that CCND1 G870A genetic polymorphism was a risk factor for lung cancer under homozygote model (OR = 1.18; 95 % CI = 1.02, 1.37), recessive model (OR = 1.21; 95 % CI = 1.03, 1.41), and allele model (OR = 1.11; 95 % CI = 1.02, 1.21). In the subgroup analysis by source of ethnicity, a statistical increase of lung cancer risk was found among Asian groups for allele model (OR = 1.11; 95 % CI = 1.01–1.22). The present meta-analysis suggests that CCND1 G870A polymorphism may be a risk factor for lung cancer. Besides, allele A may contribute to increased lung cancer risk.
Literature
1.
2.
Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
3.
Pharoah PD et al. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850–60.PubMedCrossRef
4.
Asami S et al. Increase of a type of oxidative DNA damage, 8-hydroxyguanine, and its repair activity in human leukocytes by cigarette smoking. Cancer Res. 1996;56(11):2546–9.PubMed
5.
Ceschi M et al. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26(8):1457–64.PubMedCrossRef
6.
Forsti A et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep. 2004;11(4):917–22.PubMed
7.
Hunter DJ et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870–4.PubMedCrossRef
8.
Krippl P et al. The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003;82(3):165–8.PubMedCrossRef
9.
10.
Shu XO et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev. 2005;14(1):91–7.PubMed
11.
Yu CP et al. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat. 2008;107(1):95–102.PubMedCrossRef
12.
Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61(16):6042–5.PubMed
13.
Grieu F et al. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res. 2003;23(5b):4257–9.PubMed
14.
Grunhage F et al. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis. 2008;23(2):147–54.PubMedCrossRef
15.
Hong Y et al. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur J Cancer. 2005;41(7):1037–44.PubMedCrossRef
16.
Huang WS et al. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan. Dis Colon Rectum. 2006;49(5):602–8.PubMedCrossRef
17.
Jiang J et al. Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population. J Cancer Res Clin Oncol. 2006;132(3):193–9.PubMedCrossRef
18.
Kong S et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst. 2001;93(14):1106–8.PubMedCrossRef
19.
Geddert H et al. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 2005;131(12):803–8.PubMedCrossRef
20.
Song JH et al. Association of cyclin D1 G870A polymorphism with susceptibility to gastric cancers in Korean male patients. Neoplasma. 2007;54(3):235–9.PubMed
21.
Koike H et al. Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res. 2003;23(6D):4947–51.PubMed
22.
Wang L et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 2003;103(1):116–20.PubMedCrossRef
23.
Casson AG et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 2005;104(4):730–9.PubMedCrossRef
24.
Jain M et al. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 2007;31(3):225–32.PubMedCrossRef
25.
Yu C et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2003;12(2):176.PubMed
26.
Zhang J et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer. 2003;105(2):281–4.PubMedCrossRef
27.
Ito M et al. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Urology. 2004;64(1):74–8.PubMedCrossRef
28.
Ryk C et al. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett. 2006;241(1):142–9.PubMedCrossRef
29.
Sanyal S et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25(5):729–34.PubMedCrossRef
30.
Wang L et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23(2):257–64.PubMedCrossRef
31.
Yu J et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol. 2004;172(6 Pt 1):2410–3.PubMedCrossRef
32.
Lammie GA et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene. 1991;6(3):439–44.PubMed
33.
Chen X et al. CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population. DNA Cell Biol. 2012;31(6):1107–13.PubMedCrossRef
34.
35.
36.
Betticher DC et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11.PubMed
37.
Betticher DC et al. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br J Cancer. 1997;75(12):1761–8.PubMedCrossRef
38.
Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011;4(6):779–82.CrossRef
39.
Gautschi O et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55(1):1–14.PubMedCrossRef
40.
Qiuling S et al. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003;24(9):1499–503.PubMedCrossRef
41.
Hsia TC et al. Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients. Anticancer Res. 2011;31(10):3601–5.PubMed
42.
Sobti RC et al. Effects of cyclin D1 (CCND1) polymorphism on susceptibility to lung cancer in a North Indian population. Cancer Genet Cytogenet. 2006;170(2):108–14.PubMedCrossRef
43.
Buch S et al. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005;42(4):222–8.PubMedCrossRef
44.
Gautschi O et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2006;51(3):303–11.PubMedCrossRef
45.
Hung RJ et al. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case–control study in Central Europe. Cancer Res. 2006;66(16):8280–6.PubMedCrossRef
46.
Wang W et al. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007;13(19):5974–81.PubMedCrossRef
47.
Guan P et al. Association of the hOGG1 Ser326Cys polymorphism with increased lung cancer susceptibility in Asians: a meta-analysis of 18 studies including 7592 cases and 8129 controls. Asian Pac J Cancer Prev. 2011;12(4):1067–72.PubMed
48.
Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–74.PubMedCrossRef
49.
50.
Buch SC et al. Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer. Mol Carcinog. 2012;51 Suppl 1:E11–20.PubMedCrossRef
51.
Liang YW et al. Preclinical activity of simvastatin induces cell cycle arrest in g1 via blockade of cyclin d-cdk4 expression in non-small cell lung cancer (NSCLC). Int J Mol Sci. 2013;14(3):5806–16.PubMedCrossRef
52.
Yue W et al. Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis. Clin Lung Cancer. 2011;12(1):43–50.PubMedCrossRef
53.
Camidge DR. Cell cycle-associated kinases as targets for therapy in lung cancer. J Thorac Oncol. 2010;5(12 Suppl 6):S461–2.PubMedCrossRef
54.
Wang R et al. The association of cyclin d1 (a870g) polymorphism with susceptibility to lung cancer in northern Chinese population. Tumor. 2003;23:364–6. Article in Chinese.
55.
Wang Q et al. The relationship between the cyclin d1 (ccnd1) a870g gene polymorphism and non-small cell lung cancer in Yunnan. Med Philos. 2008;29:36–8. Article in Chinese.
56.
Li QP et al. Comparative study of polymorphism of cyclin d1 gene in patients with non-small cell lung cancer from Xuanwei and Kunming. Shangdong Yi Yao. 2009;49:1–3. Article in Chinese.
Metadata
Title
The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis
Authors
Changxi Zhou
Huaijie An
Mingdong Hu
Qinghui Liu
Peiliang Geng
Jiancheng Xu
Baojun Sun
Changting Liu
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0968-8

Other articles of this Issue 6/2013

Tumor Biology 6/2013 Go to the issue

Research Article

Current evidences on IL1B polymorphisms and lung cancer susceptibility: a meta-analysis

Research Article

Thrombomodulin mediates the progression of epithelial ovarian cancer cells

Research Article

Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma

Research Article

AdHu5-apoptin induces G2/M arrest and apoptosis in p53-mutated human gastric cancer SGC-7901 cells

Research Article

Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma

Research Article

Prognostic value of cyclin E expression in breast cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits